Please ensure Javascript is enabled for purposes of website accessibility

A Star-Laden Biotech SPAC Worth Considering

By Brian Orelli, PhD and Keith Speights - Apr 17, 2021 at 9:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This healthcare-focused SPAC checks all the boxes -- except the company it plans to merge with.

In this video from Motley Fool Live, recorded on March 22, Fool.com contributors Brian Orelli and Keith Speights discuss the prospects for Revolution Health Acquisition Corp. (REVH.U 0.00%). The healthcare-focused special purpose acquisition company (SPAC) is sponsored by ARCH Ventures and General Catalyst and has some solid leadership at the helm, including former CEO of Vertex (VRTX 3.74%) Jeffrey Leiden who serves as the SPAC's chairman.

Brian Orelli: Moving on to Revolution Health Acquisition Corp, they IPOed last week. This is yet another special acquisition corporation (SPAC).

I'm generally not interested in handing my money over to someone else to invest, which is basically what you're doing when you invest in a blank check SPAC company before the merger is announced. I would certainly invest in SPAC between the announced merger and the actual merger if I thought there was a good valuation play there.

But this one has me intrigued. It's formed by ARCH Ventures and General Catalyst. Jay Markowitz, the former analyst and Regeneron senior vice president who is now at ARCH, is going to be the CEO. Then Jeffrey Leiden, who we both know because he is the former CEO of Vertex, and we're both shareholders there. He's going to be the chairman. Then on the board is going to be Catherine Friedman, who's the chair of GRAIL, and Jennifer Schneider, who is the former president of Livongo before Teladoc (TDOC 1.51%) bought them. Bob Nelson from ARCH, of course, and Hemant Taneja from General Catalyst, they're obviously going to be involved. They are going to be looking for opportunities in mental health and in home-based care, possibly also data-driven care, population health, and various other chronic conditions. They're basically covering [laughs] and they invest in everything.

Keith Speights: Everything. [laughs]

Orelli: Anything and everything healthcare-related. What do you think of the lineup and are you interested in giving Leiden some of your money to invest?

Speights: [laughs] Brian, let me first say I agree with you. I'm not necessarily a fan of getting my money to these blank check companies. Hey, I would probably be very reluctant to give a blank check to a close family member, much less [laughs] some folks I've never met. Yeah, I'm very skeptical about the early-stage SPACs where they haven't announced a partner yet.

But I'm like you, I'm intrigued by this one. You're right. They have an all-star lineup on their management team, Board of Directors. They're going after a big opportunity here, I think. It's a tremendous opportunity to, I think, go create a Livongo Health type of digital health company focusing on mental health, if that's indeed what they really focus on and stay on that. I think if they focus on that niche and maybe home-based care as well, like you mentioned, those are both fast-growing markets that I think there's a huge unmet need.

I was looking just to see and get a picture of what the mental health market is in the US. Around $212 billion are spent each year on all aspects of mental health. That's a big market to target. Of course, aging in place is going to continue to be a growth story as more Americans age and they don't want to go to an assisted living facility or a skilled nursing facility. I think both mental health and this home-based care opportunities, I think both of them are really smart to go after. This SPAC has put together a great team. The question is what happens next? I'm not at that point to say, "Yeah, I would want to go buy this SPAC, but it definitely is one I want to watch."

Orelli: The thing I don't like is the mental health part because while it's a huge opportunity, running clinical trials for mental health is just really difficult because it's patient-based and there's always a huge placebo effect where a lot of placebo patients get better, even though they're on placebo. Really, I try to stay away from mental health just for that reason.

Speights: Yeah, from a biotech standpoint, I totally agree. It's a minefield. Now, if they focus more on digital health management, I was assuming they would go after something like a Livongo that does something along the mental health lines. Maybe I'm just imagining something that doesn't exist. But I think there might be some opportunities there. I agree with you on the drug space, that's a tough area to get into.

Orelli: Yeah. That makes more sense.

Brian Orelli, PhD owns shares of Vertex Pharmaceuticals. Keith Speights owns shares of Teladoc Health and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Revolution Healthcare Acquisition Corp. Stock Quote
Revolution Healthcare Acquisition Corp.
REVH.U
$9.86 (0.00%) $0.00
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$305.53 (3.74%) $11.01
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$40.93 (1.51%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.